Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The future of clinical trials: How to ensure compliance in a decentralized model
The impact of the COVID-19 pandemic continues to resonate in every sector. Biopharma is no exception. Supply chains have been strained to breaking point. Clinical trials have been suspended or reconfigured. The assumptions underpinning distribution models have been overturned.
Under considerable pressure to sustain some sort of ‘business as usual’ – and mitigate the impact on patients’ lives – the industry had to find alternative ways of working, such as utilizing new routes and adjusting study protocols, including a rise in demand for direct-to-patient delivery for clinical trials.
As part of our response to this unique situation, World Courier undertook research to better understand customers’ perceptions of the impact of the pandemic. Chief among our findings was a major shift to decentralized trials, and a possible permanent move away from just-in-time distribution.
During this presentation, World Courier’s Kelly Frend, Personalized Supply Chain Manager, and Arnold Bernard, Senior Manager, Specialty Group, will explore the direct-to-patient delivery model for clinical trials as well as new decentralization dispense models and the impact on how drugs and treatments are administered. They will assess the importance of examining the potential implications of a decentralized model, emphasizing compliance requirements and data protection.